News | Left Atrial Appendage (LAA) Occluders | October 20, 2016

SentreHeart Announces Closing of $35 Million Funding Round for aMAZE Trial

Trial will evaluate the Lariat Suture Delivery Device as adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation

SentreHeart, Lariat Suture Delivery Device, financing round, aMAZE Trial

October 20, 2016 — SentreHeart Inc. announced in late September the closing of a $35 million Series D round of financing. Deerfield Management Company, a healthcare investment firm, led the financing, which included participation from SentreHeart’s existing investors U.S. Venture Partners, Prospect Ventures, Vivo Capital and Decheng Capital.

The proceeds will be utilized to complete the aMAZE (alternative-MAZE) randomized, pivotal clinical trial evaluating the use of the Lariat device for closure of the left atrial appendage (LAA) as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation (AFib). Deerfield Partner Ted Huber will join SentreHEART’s Board of Directors.

Recent studies have demonstrated that the Lariat device not only closes the LAA mechanicallyi, but can also isolate electrical activity within the LAAii, a known contributor for AFibiii. The objective of the aMAZE Trial is to demonstrate that Lariat for LAA closure, plus a pulmonary vein isolation (PVI) ablation, will lead to a reduced incidence of recurrent AFib compared to PVI alone, with a high safety profile.

The Lariat Suture Delivery Device is indicated for suture placement and knot tying in surgical procedures where soft tissues are being approximated and/or ligated with a pre-tied polyester suture. SentreHeart received U.S. Food and Drug Administration (FDA) 510(k) clearances for the device in 2006, 2009 and 2014. It also has CE Mark approval in Europe.

For more information: www.amazetrial.com

 

i Bartus K, et al. Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients with Atrial Fibrillation. J Am Coll Cardiol 2013 Jul 9;62(2):108-18.

ii Han FT, et al. The Effects of LAA Ligation on Electrical Activity. Heart Rhythm. 2014 May; 11(5):864-70.

iii Di Biase L, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010 Jul 13;122(2):109-18.

Related Content

ECRI Institute, mergers and acquisitions service
News | Business| January 17, 2017
ECRI Institute announced a new mergers and acquisitions service that empowers new hospital alliances to control their...
Medtronic, CoreValve Evolut R 34 mm valve, TAVI, CE Mark, European launch
News | Heart Valve Technology| January 17, 2017
Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the CoreValve Evolut R 34 mm valve...
MD Buyline, James Laskaris, four medical technology innovations, very near future
Feature | Cardiac Imaging| January 17, 2017
James Laskaris, emerging technology analyst at MD Buyline, recently offered his perspective on new medical technology...
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Edwards, Sapien transcatheter heart valve, PARTNER trial, five-year echo data, TCT 2016
News | Heart Valve Technology| November 01, 2016
Edwards Lifesciences Corp. announced new five-year hemodynamic data from the PARTNER Trial demonstrating excellent...
Overlay Init